ranitidine   Click here for help

GtoPdb Ligand ID: 1234

Synonyms: AH-19065 | Gavilast® | GR-122311X | Zantac®
Approved drug
ranitidine is an approved drug (FDA (1977))
Compound class: Synthetic organic
Comment: There is some ambiguity in the exact stereochemistry of ranitidine as represented in the literature and on other databases. The structure shown here matches that in the PubChem entry above. Other common representations include CID 657345. N.B. The structure shown in the INN document does not have a charge.
Marketed formulations may contain ranitidine hydrochloride (PubChem CID 3033332).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ranitidine

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 108.88
Molecular weight 314.14
XLogP 1.28
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CNC(=C[N+](=O)[O-])NCCSCc1ccc(o1)CN(C)C
Isomeric SMILES CN/C(=C\[N+](=O)[O-])/NCCSCc1ccc(o1)CN(C)C
InChI InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+
InChI Key VMXUWOKSQNHOCA-UKTHLTGXSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Ranitidine was used (until its withdrawl in many countries in 2020) in the treatment of gastic ulcers, where blocking of H2 receptors reduces gastric acid secretion and ameliorates disease symptoms. At the beginning of April 2020 the FDA withdrew marketing authorisation for all ranitidine products, after excess levels of the hepatotoxic and carcinogenic chemical N-nitrosodimethylamine (NDMA) were detected in ranitidine medications [1,4]. Mylan had voluntarily recalled prescription nizatidine capsules for the same reason in January 2020. Other regulatory agencies also withdrew their marketing authosisations following this contamination problem.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Competitive inhibition of H2 receptors on parietal cells leads to supression of gastric acid secretion.
External links Click here for help
For extended ADME data see the following:

Electronic Medicines Compendium (eMC)